Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO 2016 Notebook: Pricing And Innovation Hot Topics In San Francisco

This article was originally published in The Pink Sheet Daily

Executive Summary

Biopharma executives were hammered on drug pricing during the JP Morgan conference in January; now they've back in San Francisco and appear prepared to strike back with a united message: all stakeholders must work together.

You may also be interested in...



Arena Updates Etrasimod Timelines, Introduces New Drug Candidate

CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.

An Alzheimer’s Win: How Lilly Designed Donanemab Trial To Succeed

Lilly took a different path to positive results in Alzheimer’s with a smaller, biomarker-driven study to test the hypothesis that rapid, robust clearance of amyloid could slow disease progression, CEO David Ricks explains at J.P. Morgan.

An Alzheimer’s Win: How Lilly Designed Donanemab Trial To Succeed

Lilly took a different path to positive results in Alzheimer’s with a smaller, biomarker-driven study to test the hypothesis that rapid, robust clearance of amyloid could slow disease progression, CEO David Ricks explains at J.P. Morgan.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel